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Abstract
Background
Truncating titin (TTN) mutations, especially in A-band region, represent the most common
cause of dilated cardiomyopathy (DCM). Clinical interpretation of these variants can be
challenging, as these variants are also present in reference populations. We carried out sys-
tematic analyses of TTN truncating variants (TTNtv) in publicly available reference popula-
tions, including, for the first time, data from Exome Aggregation Consortium (ExAC). The
goal was to establish more accurate estimate of prevalence of different TTNtv to allow better
clinical interpretation of these findings.
Methods and Results
Using data from 1000 Genomes Project, Exome Sequencing Project (ESP) and ExAC, we
estimated the prevalence of TTNtv in the population. In the three population datasets, 52–
54% of TTNtv were not affecting all TTN transcripts. The frequency of truncations affecting
all transcripts in ExAC was 0.36% (0.32% - 0.41%, 95% CI) and 0.19% (0.16% - 0.23%,
95% CI) for those affecting the A-band. In the A-band region, the prevalences of frameshift,
nonsense and essential splice site variants were 0.057%, 0.090%, and 0.047% respec-
tively. Cga/Tga (arginine/nonsense–R/*) transitional change at CpGmutation hotspots was
the most frequent type of TTN nonsense mutation accounting for 91.3% (21/23) of arginine
residue nonsense mutation (R/*) at TTN A-band region. Non-essential splice-site variants
had significantly lower proportion of private variants and higher proportion of low-frequency
variants compared to essential splice-site variants (P = 0.01; P = 5.1 X 10−4, respectively).
Conclusion
A-band TTNtv are more rare in the general population than previously reported. Based on
this analysis, one in 500 carries a truncation in TTN A-band suggesting the penetrance of
these potentially harmful variants is still poorly understood, and some of these variants do
not manifest as autosomal dominant DCM. This calls for caution when interpreting TTNtv in
individuals and families with no history of DCM. Considering the size of TTN, expertise in
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Introduction
Titin (TTN) is a giant muscle protein expressed in the cardiac and skeletal muscles. It spans half
of the sarcomere from Z-line to M-line. Titin is known to play a key role in muscle assembly,
force transmission at the Z-line and maintenance of resting tension in the I-band region. The
clinically relevant A-band of TTN binds to the thick filament, where it may regulate filament
length and assembly, and is thought to be critical for biomechanical sensing and signaling. The
C-terminal M-band contains a strain-sensitive kinase, which may have a role in cardiac signal
transduction [1]. Before the era of next generation sequencing (NGS) only a small number of
TTN gene mutations have been found to associate with cardiomyopathies [1–8]. This has largely
been due to the difficulty to sequence large TTN gene with its ~363 exons. Consequently, TTN
mutation frequency and therefore clinical impact were unknown.
Recently, using a combination of NGS and dideoxy sequencing, Herman et al. [9] esti-
mated TTN truncating variants (TTNtv)—nonsense, frameshift and essential splice site, to
be responsible for approximately 25% of familial cases of idiopathic dilated cardiomyopathy
(DCM) and 18% of sporadic cases in a large cohort of subjects. Similarly to Herman et al. [9],
in our recent study on Finnish patients with DCM, TTNtv were responsible for 20.6% of
cases with family history of DCM. Furthermore, in both studies and others the mutations
were not randomly distributed along the TTN gene as the bulk of the mutations were located
predominantly in the A-band region and affecting all transcripts of TTN [10–14]. Another
recent study confirmed that TTN truncations are highly enriched in DCM patients when
compared to healthy controls [10]. Furthermore, identifying a truncating variant in the A-
band region was estimated to have 93% risk of being disease causing. They also determined
that C-terminal truncations affecting all transcripts were more pathogenic and mediated
their effects through dominant negative mechanisms rather than haploinsufficiency. Roberts
et al. [10] also confirmed that TTNtv-positive DCM patients manifest more severe clinical
phenotypes than TTNtv-negative DCM patients. Recently, TTNtv have also been identified
in patients with clinical features of both left ventricular non-compaction cardiomyopathy
(LVNC) and dilated cardiomyopathy [15].
Utilization of reference population databases has significantly improved our ability to inter-
pret genetic findings. Before the publishing of Exome Aggregation Consortium (ExAC) data-
base in 2014, we have been dependent on the different versions of the 1000 Genomes Project
and the National Heart Lung Institutes Exon Sequencing Projects (ESP) [16, 17]. Since the
inception of 1000 Genomes in 2010, various phases, versions and releases of the project have
evolved, with the phase 3 variants (which represents the final phase of the project) being based
on data from 2535 individuals from 26 different populations around the world, with 60–100
individuals representing each population in the cohort. The quality and coverage of sequencing
data in this database have varied significantly during the evolution of the database causing high
prevalence of false positive insertion-deletions (INDELs) in earlier datasets. Recent effort by
Golbus et al. [18] to estimate the prevalence of TTNtv in the population used the February
2012 release (phase 1 version 2) containing variants and phased genotypes across 1092
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individuals from 14 different populations. In this study, the prevalence of frameshift INDELs
that disrupt TTN was estimated to be as high as 3.2% (35/1092) among reference individuals.
In the study by Roberts et al. [10], the prevalence of TTNtv was estimated 2% using a combina-
tion of 1000 Genomes call set (phase 1 version 3) and ESP call set.
Since the prevalence of TTNtv in reference populations is a critical determinant when inter-
preting genetic test results, we pursued to analyze this, for the first time, in the over 60 000
ExAC cohort together with the final version of 1000 Genomes project and ESP datasets. Our
goal was also to define the specific prevalence of different TTNtv in various TTN domains to
better understand the distribution and prevalence of different genetic findings. Our study
reveals that identifying a frameshift, nonsense or an essential splice-site variant in the critical
A-band of TTN is a rare event. In our study we conclude that in reference population only 1 in
1750 individuals carry a frameshift, 1 in 1100 carry a nonsense, and 1 in 2100 carry an essential
splice variant in TTN A-band region that is estimated to affect all isoforms of the gene. We also
determine the characteristics of nonsense variants identified and variability in the splice-site
regions of TTN gene. We believe our results have a wide application in clinical interpretation
of genetic test results and further emphasize that TTNtv in general population exceed signifi-
cantly the prevalence of DCM associated with TTN truncations.
Methods
1000 Genomes Project Data
TTN gene variant data from the various phases and versions of 1000 Genomes Project were
retrieved, and truncating variants comprising of splice, nonsense and frameshift variants were
used for analysis.
Analysis of TTN Truncations in the Population
Considering the INDELs filtering on 1000 Genomes Project phase 1 variant call sets (ftp://ftp.
1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/README.phase1_integrated_release_
version3_20120430) and the release of the phase 3 call set, we were keen to re-estimate the fre-
quency of TTN truncating mutations in the population. We downloaded the exonic boundaries
of TTN from the Ensembl Genome Browser (www.ensembl.org), and extracted exonic variants
from the three versions of the phase 1 variants call sets (V1, V2, V3), and the version 5 (V5) of
the phase 3 variants call set available in the 1000 Genomes Project database. Only calls that
passed all quality filters were used for downstream analysis.
Exome Sequencing Project (ESP) and Exome Aggregation Consortium
(ExAC) Data
In a bid to capture a complete map of population TTN truncations and to further filter likely
false positives in the latest release of 1000 Genomes Project, we utilized variants reported in
two other well-annotated databases–Exome Sequecing Project (ESP) [17] and ExAC [19], with
over 6500 and 60700 individuals respectively. As 1000 Genomes Project cohorts and ESP
cohorts were part of the ExAC project cohorts, we filtered TTN truncating variants unique to
either 1000 Genomes Project or ESP call sets. Variants located in novex-specific exons and
exons specific to few transcripts of TTN were filtered before filtering for sequencing coverage/
depth. See below for more details on the workflow and results.
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Results
TTN Truncating Variants in the Evolution of 1000 Genomes Project
We extracted TTNtv that passed all quality filters as reported by the 1000 Genomes Project
from various phases and versions of the project. Based on the total number of TTNtv in each
version of the phase 1, and the version 5 of the phase 3 releases, we estimated the prevalence of
TTNtv in the population. Interestingly, we observed a downward trend in both the number of
TTNtv and TTNtv prevalence from the oldest to the latest release of the project (Fig 1). Version
2 of the phase 1 release contained predominantly rare TTNtv with high call qualities as against
version 1 TTNtv composed of predominantly common TTNtv with very low qualities.
To demonstrate how the quality of sequencing and bioinformatic analysis contributes to
our understanding of variant frequencies in general population, especially when estimating
INDELS, we evaluated the detection rates of TTNtv in the evolution of 1000 Genomes project
(see discussion) (Fig 1). The initial phase 1 (V1) integrated data contained 22 truncating muta-
tions: 4 nonsense, 1 splice region, and 17 frameshift mutations (16 of which were single nucleo-
tide (SN) INDELs) (S1 Table). After the first INDELs filtering on version 1 of the phase 1
integrated variant call set, six of the SN INDELs were filtered as false positives in the set due to
technical artifacts introduced in the sequencing step. Version 2 phase 1 integrated variant call
set contained 16 TTNtv: 4 nonsense, 1 splice region, and 11 frameshifts (10 SN INDELs)
reported in Golbus et al. [18] study. All frameshift mutations as well as splice region variant
Fig 1. Influence of 1000 genomes project evolution on titin truncation prevalence. Abbreviations:
P1V1 –phase 1 version 1; P1V2 –phase 1 version 2; P1V3 –phase 1 version 3; P3V5 –phase 3 version 5.
doi:10.1371/journal.pone.0145284.g001
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were filtered out as false positives in the version 3 of the phase 1 integrated variant call set (S2
and S3 Tables). We identified thirty-three TTNtv in the phase 3 integrated variant call set of the
1000 Genomes Project: 1 frameshift, 13 splice and 19 nonsense. Interestingly, a vast majority of
the splice site and nonsense variants were located in either novex-3 specific exon, exons either
not expressed or with low expression in human left ventricle (LV), described by Roberts et al.
[10] as proportion spliced-in (PSI) values or in exons not affecting all transcripts of the gene. Fur-
thermore, several of the nonsense variants were located in regions with low coverage, suggesting
they are likely false positives. In this analysis we demonstrate a marked reduction in the preva-
lence of TTNtv during the evolution and improvement of 1000 Genomes Project (Fig 1). The
variants of the final phase (phase 3) were used in the analyses as our 1000 Genomes dataset.
TTN Truncating Variants in General Population
In our goal to accurately estimate the prevalence of TTNtv in the general population, we que-
ried TTNtv in 1000 Genomes, ESP and ExAC databases (Table 1). The workflow is described
in Fig 2. With our strategy, we were able to filter likely false positives unique to either 1000
Genomes or ESP variants. Of note, only three splice-site variants were shared between 1000
Genomes and ESP TTN truncation call sets suggesting that ESP is enriched with population
specific variants, as it is made up of primarily Americans either of European (EA) or African
(AA) origin. Furthermore, at least 52% of TTNtv (1000Genomes: 52% - 17/33; ESP: 54% - 36/
66; ExAC: 53% - 247/470) found in the populations were located in exons that are not present
in all transcripts and estimated to have low probability of pathogenicity.
When comparing the prevalence of TTNtv that affect all transcripts (excluding Novex-3
specific and low PSI exon variants) in ExAC vs 1000 Genomes, we identified lower frequency
of nonsense mutations in ExAC cohort compared to 1000 Genomes cohort (0.16% vs. 0.28%,
respectively) (Table 1). This was also the trend in nonsense variants identified only in the A-
band region (0.09% vs. 0.23%) (Table 1). Essential splice site variants were very rare in ExAC
database (0.047%) and were absent in 1000 Genomes and ESP. When evaluating the TTNtv
that affect all transcripts in ExAC reference population by TTN band, 11.0% (19/173) are
located in the Z-band; 22.6% (39/173) in the I-band; 52.0% (90/173) in the A-band; and 14.5%
(25/173) in the M-band (Table 1 and Fig 3). Based on cohort size, the ExAC database gave the
most reliable result in this analysis as some subtypes of TTNtv were absent in either 1000
Genomes or ESP call sets (Table 1). In the ExAC database the total prevalence of TTNtv affect-
ing all transcripts was 0.36% (0.315% - 0.413%, 95% CI). Given that low coverage regions are
often enriched with false-positive INDELs, we rendered the histogram of the TTNtv coverage
data from ExAC and found out that about 80% of the variants have coverage of at least 50x.
Moreover, we estimated TTNtv prevalence without introducing coverage filter and found out
that despite the little increase in the number of variants, the prevalence did not increase signifi-
cantly (0.46%) and falls within the confidence interval of the prevalence estimate with coverage
filter.
The prevalence of TTNtv in clinically relevant A-band was 0.19%, suggesting that 1 in 500
individual carries one of the subtypes of TTNtv. When evaluating by mutation subtype, we
conclude that in reference population, only 1 in 1100 individuals carries a nonsense mutation;
1 in 1750 carries a frameshift, and 1 in 2100 carries an essential splice site variant in TTN
A-band region that is estimated to affect all transcripts.
Distribution of TTN Truncating Variants by Ethnicity
Frequencies of TTNtv vary significantly between different ethnic groups (African population
[AFR]: 0.46%, American population [AMR]: 0.50%, European population [EUR]: 0.27%, Asian
Titin Truncation Is a Rare Event in General Population
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population [AS]: 0.53%; P = 2.7 × 10−5). AS has the highest frequency of TTNtv while the Euro-
pean population has the least. The frequency of TTNtv in East Asian population (EAS), though
lower, is not significantly different from that of the South Asian Population (SAS) (EAS: 0.37%
vs. SAS: 0.62%; P = 0.091). Similarly, the frequency of TTNtv in Finnish European population
(FIN) is lower but statistically indistinct when compared with the non-Finnish Europeans
(NFE) (FIN: 0.12% vs. NFE: 0.28%%; P = 0.125).
Golbus et al. [18] recently reported that Asians have significantly more TTN protein altering
variants (PAV) than all other ethnic groups (28.76 variants/individual). In this study, we
have found a higher frequency of TTNtv in the Asians. Put together, this data confirms the
Table 1. Distribution and burden of TTN truncations in publicly available reference populations.
Total TTN truncating Allele Excluding novex-3 speciﬁc, low PSI and likely
false positive variants
1KG ESP ExAC 1KG ESP ExAC
Population size 2504 6504 60706 2504 6504 60706
Total TTNtv variant 29 66 470 9 16 173
Individuals 46 612 813 10 19 219
Prevalence (%)
Population 1.837 9.409 1.339 0.399 0.292 0.360
Mutation type # (Prevalence %)
Frameshift 1 (0.120) 25 (2.550) 179 (0.420) 1 (0.079) 3 (0.090) 63 (0.110)
Nonsense 15 (1.120) 28 (0.510) 177 (0.420) 7 (0.280) 11 (0.170) 72 (0.160)
Splice site 13 (0.600) 13 (6.350) 114 (0.490) 1 (0.040) 2 (0.030) 38 (0.090)
Distribution by Domain # (Prevalence %)
Z-band 1 (0.039) 2 (0.030) 28 (0.062) - 1 (0.015) 19 (0.037)
I-band 13 (0.718) 49 (8.225) 289 (0.957) 1 (0.039) 7 (0.107) 39 (0.072)
A-band 12 (0.918) 9 (0.153) 122 (0.252) 7 (0.319) 4 (0.061) 90 (0.196)
M-band 3 (0.119) 6 (0.999) 31 (0.067) 1 (0.079) 4 (0.107) 25 (0.054)
Z-disk # (prevalence %)
Frameshift - - 10 (0.016) - - 8 (0.013)
Nonsense - 1 (0.015) 8 (0.013) - 1 (0.015) 4 (0.006)
Splice site 1 (0.039) 1 (0.015) 10 (0.032) - - 7 (0.018)
I-band # (prevalence %)
Frameshift - 17 (0.261) 109 (0.303) - - 10 (0.016)
Nonsense 4 (0.276) 20 (0.307) 103 (0.265) 1 (0.039) 5 (0.076) 19 (0.034)
Splice site 9 (0.434) 12 (0.184) 77 (0.388) - 2 (0.030) 10 (0.021)
A-band # (prevalence %)
Frameshift 1 (0.079) 4 (0.061) 50 (0.082) 1 (0.079) 1 (0.015) 35 (0.057)
Nonsense 10 (0.789) 5 (0.076) 49 (0.112) 6(0.239) 3 (0.046) 37 (0.090)
Splice site 1 (0.039) - 23 (0.057) - - 18 (0.047)
M-band # (prevalence %)
Frameshift - 4 (0.061) 10 (0.023) - 2 (0.030) 10 (0.006)
Nonsense 1 (0.039) 2 (0.030) 17 (0.034) - 2 (0.030) 12 (0.024)
Splice site 2 (0.079) - 4 (0.009) 1 (0.039) - 3 (0.006)
Titin truncations in 1000 Genomes project (Phase 3), Exome Sequencing Project, and ExAC databases. The number of alleles and population prevalence
for each variant is shown. Variants were ﬁltered to exclude variants with low probability of pathogenicity (location in novex-speciﬁc and other exons with
low expressions in LV). Abbreviations: 1KG– 1000 Genomes project; ESP–Exome Sequencing Project; ExAC—Exome Aggregation Consortium; PSI–
Proportion Spliced-In
doi:10.1371/journal.pone.0145284.t001
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enrichment of not only TTN PAV but also TTNtv in the Asian population (SAS in particular)
compared to other ethnic groups.
Nonsense TTN SNPs in Reference Population
We examined the patterns and the positions of the TTN nonsense SNPs in the population. Out
of the twenty-three possible ways to change codons into stop codons (nine, seven and seven for
the first, second and third positions, respectively), twenty-one were found in reference popula-
tion, with tCg/tAg and tgT/tgA being absent. Nonsense SNPs were more frequent at the first
codon position than at the second and third positions (P = 5.2 × 10−11, chi-square test). The
most frequent type of nonsense mutation in the TTN gene was the change from Cga to Tga
(R/). Of note, the Cga/Tga transitional change at CpG mutation hotspots accounts for 91.3%
(21/23) and 62% (21/34) of arginine residue nonsense mutations (R/) at TTN A-band region
and all TTN CpG hotspot nonsense mutations in the population data respectively. Interest-
ingly, 36.1% (13/36) of R/ found in reference population have been reported in Catalogue of
Somatic Mutations in Cancer (COSMIC) database [20].
Splice Site Variants in Reference Population
Of the total splice site/region variants, 86.9% (324/373) were non-essential splice variants
located>2bp into the intronic region, with 52.8% (197/373) of the variants affecting TTN
A-band exons. Of note, majority, 88.8% (175/197), of the splice variants affecting A-band
exons were non-essential splice-site variants. When analyzing all essential splice site variants,
we identified that 83.7% (41/49) were private. In contrast, non-essential splice-site variants had
Fig 2. Flowchart for analysis of TTN truncations in publicly available reference populations. Abbreviations: 1KG– 1000 Genomes project; ESP–
Exome Sequencing Project; ExAC—Exome Aggregation Consortium; LV–Left ventricle.
doi:10.1371/journal.pone.0145284.g002
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significantly lower proportion of private variants and higher proportion of low-frequency vari-
ants when compared to essential splice-site variants (P = 0.01; P = 5.1 × 10−4, respectively). The
significance increases with increasing distance away from essential splice site (Fig 4).
Discussion
By evaluating the ExAC reference population of over 60 000 individuals, we showed that
TTNtv affecting all transcripts occur in 0.36% (0.315% - 0.413%, 95% CI) of the general popu-
lation. These types of truncations in clinically relevant A-band can be detected in 0.19% of ref-
erence population. When evaluating the mutation types separately, the prevalence of each
mutation type in A-band was lower than 0.1%, below a commonly used filtering criterion
when searching for disease-causing mutation of rare dominantly inherited diseases. Further-
more, we provide insights on the position, type and frequency of nucleotide change(s) leading
to nonsense mutations in TTN, and showed that non-essential splice-site variants in TTN have
a tendency of being frequent in general population. In addition, we describe how increased
quality of data analysis and larger number of reference individuals in 1000 Genomes Project
has markedly reduced the prevalence of TTNtv in this database.
The 1000 Genomes Project published the pilot phase of the project in 2010. This release rep-
resents data from low-coverage (~2-fold– 6-fold) whole-genome sequencing of 179 individuals,
high-coverage (~42-fold) whole-genome sequencing of 6 individuals in 2 trios, and exon-tar-
geted sequencing (> 50-fold coverage) of 8140 exons in 697 individuals [16]. This was followed
by Phase 1 project release that represents low coverage exome data available for the first 1092
samples. Phase 2 represents an expanded set of samples, around 1700 in number, and it was
used for method development to both improve existing methods from phase 1. Furthermore, it
Fig 3. Spatial distribution of titin frameshift, nonsense and splice-site mutations in reference populations. Titin is linearly depicted with its 152 Ig-like
domains in green and 132 fibronectin type III domains in purple. TTNtv are shown as lollipops and bars. Depicted are nonsense (red) and frameshift (green)
mutations in various phases of the 1000 Genomes project. Dark grey bars represent the complete map of various TTNmutations from ExAC. Variants are
shown relative to the titin Uniprot Sequence identifier Q8WZ42. The dashed lines below the protein schematic indicate the location of variants within the
sarcomere. Abbreviations: 1KG– 1000 Genomes project; ESP–Exome Sequencing project; ExAC—Exome Aggregation Consortium; V–version.
doi:10.1371/journal.pone.0145284.g003
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was used to develop new methods to handle features like multi-allelic variant sites and true
integration of complex variation and structural variants. The phase 1 integrated release, based
on low coverage and exome data, contains phased genotypes for 1092 individuals from 14 pop-
ulations, and the variants have been extensively used in several studies to draw conclusions on
human genetic variations [18, 21, 22]. Although significantly improved, the data still contained
higher fraction of frameshift INDELs in low-coverage regions suggesting high prevalence of
false positive frameshifts. Subsequent filtering of these false positives resulted in version 2 (V2)
and version 3 (V3) of the phase 1 integrated release. The false positive INDELs present in the
February 2012 release used in Golbus et al. [18] study has led to high estimates of truncating
TTN variants in reference population.
Nonsense mutations account for an appreciable proportion of single-basepair substitutions
affecting gene-coding region reported in Human Gene Mutation Database (HGMD). Our
Fig 4. Titin population splice site/region allele frequency spectrum. TTN population non-essential splice-site variants (>2bp) have significantly lower
proportion of private variants and higher proportion of low-frequency variants compared to essential splice-site variants (P = 0.01; P = 5.1 × 10−4,
respectively). The P-values are shown for comparison between essential splice-site (1-2bp) and non-essential splice-site variants: 3–4bp (red), 5–6bp
(green), and (blue) for combined comparison.
doi:10.1371/journal.pone.0145284.g004
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analysis shows that as in other genes, Cga/Tga (Arg/; resulting from methylation-mediated
deamination) nucleotide substitution at CpG hotspot is the most frequent nucleotide substitu-
tion leading to nonsense mutation in TTN. The cytosine-guanine (CpG) dinucleotide, though
under-represented in vertebrate genomes, has been reported to be a hotspot for pathological
mutations in the human genome [23, 24]. This hypermutability is related to its role as the
major site of cytosine methylation with the attendant risk of spontaneous deamination of
5-methylcytosine (5mC) to yield thymine [25]. In this study, we found a significant over-repre-
sentation of Arg/ CpG hotspot mutation at TTN A-band region. Interestingly, 62% of Arg/
CpG hotspot mutations are located at TTN A-band. Furthermore, a significant proportion of
TTN Arg/ CpG hotspot mutations have been reported as germ line mutations identified in
various cancer cells. This highlights the fact that the CpG is a critical hotspot for both germline
and somatic mutations. Considering the high prevalence of Arg/ CpG hotspots in A-band,
majority of exons coding for A-band present in all TTN transcripts, and that nonsense muta-
tions in this region do not lead to mRNA decay but seem to work through dominant negative
mechanism, it is not surprising that the A-band region is vulnerable to truncating mutations
that are highly enriched among DCM patients.
Epigenetic mechanisms could underlie the elevated mutation frequency in the TTN A-band
region occurring also in the germ line and manifesting hereditary cardiomyopathy. Epigenetic
mechanisms are increasingly being recognized as causes and modulators of human disease. To
date, there are few studies on the contribution of DNAmethylation to disease onset and pro-
gression in cardiomyopathy [26–28]. In 2011, Movassagh et al. [26] reported differential DNA
methylation patterns in CG dinucleotides located at the promoter, intragenic and gene bodies
CpG islands in human end-stage cardiomyopathy. Furthermore, using a single gene model,
Meurs & Kuan [28] evaluated the methylation of the CpGs within the exon regions of the skele-
tal muscle isoform of the myosin binding protein C gene (MYBPC2) and cardiac myosin bind-
ing protein C gene (MYBPC3), a common causal gene for hypertrophic cardiomyopathy.
Interestingly, the mean methylation level of CpGs was significantly higher inMYBPC3 than
MYBPC2 (P< 0.0001). These probably suggest that there are unique aspects of this cardiac
gene that may result in increased genetic mutability. As mechanisms promoting mutability
play a role in disease prevalence, evaluation of the methylation levels of TTN, and other DCM-
associated genes are warranted.
Differential splicing in regions with variable sarcomere ultrastructures accounts for the vari-
able structures of TTN I-band in different tissues. In our goal to characterize essential splice
and other splice region variants that might contribute to disease development, we examined
and compared the position (1 - 6bp into the intronic region, 1 - 2bp being essential splice site
variants) and frequency of all TTN essential splice-site and splice-region variants in the popula-
tion. While essential splice-site variants were predominantly private, we observed an increase
in allele copies of non-essential splice-site variants as the distance increases from the essential
splice-site. Robert et al. [10] recently reported lower enrichment of noncanonical splice vari-
ants in DCM compared to canonical splice variants. Our results confirm that clinical interpre-
tation of non-essential splice site variants in TTN gene is difficult and these variants should not
be claimed deleterious without RNA level evidence of splicing defect.
Several studies have reported M-line TTNmutations in various skeletal muscle diseases
including centronuclear myopathy (CM, MIM #160150) [29], tibial muscular dystrophy
(TMD, MIM #600334) [30, 31], early-onset myopathy (MIM #611705) [6], distal myopathy
and limb girdle muscular dystrophy 2J (LGMD2J, MIM #608807) [32], with or without cardiac
muscle involvement. In 2007, Carmignac et al. [6] reported the first M-line homozygous titin
truncations causing congenital titinopathy involving both cardiac and skeletal muscle. While
most heterozygous M-line titin mutations cause late-onset, dominant disorders involving
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predominantly skeletal muscle, homozygous or compound heterozygous M-line TTNmuta-
tions cause early-onset, recessive muscle and cardiac disorder. M-line TTNmutations truncate
only part of the M-band portion of TTN [6]. When such carboxy-terminal truncated titin pro-
teins are integrated into the sarcomere, they cause recessive, early-onset skeletal and cardiac
myopathy. In the case of DCM however, truncated titin proteins, though incorporated into the
sarcomere, would not include the M-band residues, as TTNtvs causing DCM were clustered in
TTN A-band but absent from Z-disk and M-band regions of TTN. The position of TTNtv caus-
ing DCM suggests a dominant negative effect. In addition, Herman et al. [9] argued that we
would expect a more uniform distribution of such mutations if more proximal TTNtv caused
DCM through haploinsufficiency. Furthermore, using RNA sequencing, Roberts et al. [10]
reported a comparable total TTN transcript levels in patients with or without TTNtv. They also
found and reported a comparable allelic expression of TTNtv and SNPs, which does not sup-
port substantial nonsense-mediated decay. Using a combination of genetic data, TTN RNA
and protein expression in LV tissues, Roberts et al. [10] also concluded that TTNtv cause DCM
by a dominant negative effect.
As majority of TTNtv have been identified at the heterozygous state in patients with spo-
radic or dominant conditions, such mutations are typically considered autosomal dominant. In
majority of the cases, dominant inheritance has been clearly established by co-segregation. To
the best of our knowledge, only a few studies have suggested recessive inheritance with TTN
mutations. In these studies, TTNtv co-occurred with a second hit but actually only eight out of
18 patients had two TTNtv, and in two of these cases, bi-allelic status was not confirmed by
parental testing [29, 33, 34]. However, Ceyhan-Birsoy et al. [29] did not evaluate the parents’
cardiac phenotype; Chauveau et al. [33] found normal echocardiography and ECG in all
parents but they were relatively young (aged 38–55 years) and thus a genotype-positive yet a
phenotype-negative status cannot be excluded. In the Evilä et al. [34] study, the other patient
with bi-allelic TTNtv had an affected father with skeletal myopathy but the patient mother’s
cardiac phenotypes were not evaluated. Interestingly, all TTNtv reported in these studies were
located in the M-line of TTN. These observations together with our prevalence estimates high-
light that recessive cardiac disease caused by titin dysfunction is possible in rare occasions. Ini-
tial evidence exists for recessive inheritance of TTNmutations in neurological disease although
clearly more comprehensive segregation studies are warranted to ease interpretation of TTNtv.
Concluding Remarks
Considering the accumulated evidence of TTN truncating mutations being the most common
cause for hereditary DCM [9–11] together with our observations on low prevalence of poten-
tially disease-causing TTNtv in general population, we emphasize that identifying a TTNtv,
especially in the A-band region and affecting all transcripts, have a potentially higher risk of
being disease causing than previously anticipated [10]. Further studies are required to elucidate
the full phenotypic spectrum of TTNtv-associated myocardial disease. It is likely that the severe
end-stage DCM or LVNC only represent the peak of the iceberg and milder disease forms that
will never develop fulminant cardiomyopathy may exist e.g. transient peripartum cardiomyop-
athy. This information is needed as it affects our interpretation of genetic variants in reference
populations and also the genetic counseling processes and clinical management. Evaluating the
TTN gene reliably in clinical setting requires expertise in DNA library preparation, high cover-
age NGS strategies, validated bioinformatics tools, confirmatory sequencing, skilled interpreta-
tion team, and ideally the inclusion of mRNA and/or protein level assessment for definite
diagnosis. Current low coverage exome and whole genome sequencing approaches may be
sub-optimal for diagnostic work-up in cardiomyopathies as their efficacy for identifying
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INDELs is weak compared to high coverage targeted sequencing strategies [35, 36]. Moreover,
the size of TTN gene makes it more susceptible than an average sized gene to false positive
truncating variant especially when using ‘clinical’ exome sequencing. It can be easily demon-
strated by the fact the there is four homozygous TTN variants (positions: 2:179610726,
2:179612587, 2:179571683, 2:179466515) in ExAC database and they are found as heterozygote
in 1, 5, 10 and 10 individuals respectively, although we would expect to find 245 heterozygotes
for one homozygote in this cohort. This indicates a high probability of detected homozygotes
being false positives. Further studies are needed to evaluate the reliability of our reference data,
and especially to find out how many of the TTNtv in reference populations are true positives.
It should be kept in mind that one out of seven low quality score variants (QS<500) in exome
sequencing are likely false positives (non-detectable by Sanger sequencing) [37].
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